Hepatitis B vaccine in Saudi children

ABSTRACT

The aim of our study is to know the protective efficacy and immunogenicity of Engerix B [Recombinant Deoxyribonucleic acid-Yeast derived Hepatitis B vaccine]. In 1987, 113 seronegative children were vaccinated intramuscularly in the quadriceps region with 1.0 ml of Engerix B. Serum samples were collected at month 1, 2, 7, 12 and tested for Anti HBs levels. The seroconversion rates for HBs Antibodies were 28% at month 1.79% at month 2.94% at month 7 and 92% at month 12. No significant adverse reactions were noticed